BioArctic: No essential impact on our valuation - Redeye

Redeye adjusts BioArctic's valuation to reflect the terminated collaboration with AbbVie. While this decision has a limited effect on the valuation - ABBV-0805 was about 7% on the total value - it impacts the binarity of the company as lecanemab is now the only asset in clinical development. At the same time, it gives the opportunity for BioArctic to find a more committed partner for the portfolio of alpha-synuclein antibodies.

Länk till analysen i sin helhet: https://www.redeye.se/research/838854/bioarctic-no-essential-impact-on-our-valuation?utm_source=finwire&utm_medium=RSS